Your search for: 'author:("Serrano, Felipe")' has returned 2 results. (0.007s) Save search

Authors: Zolezzi, Juan M. | Lindsay, Carolina B. | Serrano, Felipe G. | Ureta, Roxana C. | Theoduloz, Cristina | Schmeda-Hirschmann, Guillermo | Inestrosa, Nibaldo C.

Article Type: Research Article

Abstract: Soluble amyloid-β (Aβ) oligomers have been recognized as early neurotoxic intermediates with a key role in the synaptic dysfunction observed in Alzheimer’s disease (AD). Aβ oligomers block hippocampal long-term potentiation (LTP) and impair rodent spatial memory. Additionally, the presence of Aβ oligomers is associated with imbalanced intracellular calcium levels and apoptosis in neurons. In this context, we evaluated the effects of three diterpenes (ferruginol, jatrophone, and junicedric acid) that are found in medicinal plants and have several forms of biological activity. The intracellular calcium levels in hippocampal neurons increased in the presence of ferruginol, jatrophone, and junicedric acid, a result …that was consistent with the observed increase in CA1 synaptic transmission in mouse hippocampal slices. Additionally, assays using Aβ peptide demonstrated that diterpenes, particularly ferruginol, restore LTP and reduce apoptosis. Recovery of the Aβ oligomer-induced loss of the synaptic proteins PSD-95, synapsin, VGlut, and NMDA receptor subunit 2A was observed in mouse hippocampal slices treated with junicedric acid. This cascade of events may be associated with the regulation of kinases, e.g., protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII), in addition to the activation of the canonical Wnt signaling pathway and could thus provide protection against Aβ oligomers, which trigger synaptic dysfunction. Our results suggest a potential neuroprotective role for diterpenes against the Aβ oligomers-induced neurodegenerative alterations, which make them interesting molecules to be further studied in the context of AD. Show more

Keywords: Amyloid-β, diterpenes, ferruginol, jatrophone, junicedric acid, neuroprotection

DOI: 10.3233/JAD-170701

Citation: Journal of Alzheimer's Disease, vol. 63, no. 2, pp. 705-723, 2018

Authors: Inestrosa, Nibaldo C. | Carvajal, Francisco J. | Zolezzi, Juan M. | Tapia-Rojas, Cheril | Serrano, Felipe | Karmelic, Daniel | Toledo, Enrique M. | Toro, Andrés | Toro, Jessica | Santos, Manuel J.

Article Type: Research Article

Abstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive deterioration of cognitive abilities, accumulation of the amyloid-β peptide (Aβ), increase of oxidative stress, and synaptic alterations. The scavenging of reactive oxygen species through their matrix enzyme catalase is one of the most recognized functions of peroxisomes. The induction of peroxisome proliferation is attained through different mechanisms by a set of structurally diverse molecules called peroxisome proliferators. In the present work, a double transgenic mouse model of AD that co-expresses a mutant human amyloid-β protein precursor (AβPPswe) and presenilin 1 without exon 9 (PS1dE9) was utilized in order to …assess the effect of peroxisomal proliferation on Aβ neurotoxicity in vivo. Mice were tested for spatial memory and their brains analyzed by cytochemical, electrophysiological, and biochemical methods. We report here that peroxisomal proliferation significantly reduces (i) memory impairment, found in this model of AD; (ii) Aβ burden and plaque-associated acetylcholinesterase activity; (iii) neuroinflammation, measured by the extent of astrogliosis and microgliosis; and (iv) the decrease in postsynaptic proteins, while promoting synaptic plasticity in the form of long-term potentiation. We concluded that peroxisomal proliferation reduces various AD neuropathological markers and peroxisome proliferators may be considered as potential therapeutic agents against the disease. Show more

Keywords: Amyloid β-peptide, peroxisomal proliferation, spatial memory, synaptic plasticity, transgenic mice

DOI: 10.3233/JAD-2012-120397

Citation: Journal of Alzheimer's Disease, vol. 33, no. 4, pp. 941-959, 2013